A new nonprofit wants to streamline gene therapy for diseases often avoided by pharmaceutical companies — making treatment more like a routine procedure than a bespoke drug.
FDA Europe shows what can happen when countries let bureaucratic procedures take precedence over the well-being of people suffering from rare diseases.
Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors are closing on their options.
America has battled the war on cancer for more than half a century. Despite major advances, each new year brings millions of new cancer diagnoses and deaths. Chris Cuomo holds an intimate conversation with some of the U.S. Government’s top doctors, an FDA insider and those looking to push the research forward on why the disease hasn’t been cured and what steps could be taken to advance the search for a cure. The panel includes: The Director of the National Institutes of Health, Dr. Jay Bhattachacharya, the National Cancer Institute Director Dr. Anthony Letai, the CEO of The Parker Institute For Cancer Immunotherapy, Dr. Karen E. Knudsen, Former Associate Commissioner of the Food and Drug Administration Peter Pitts and Dr. Patrick…